Company
|
NEWS
|
Research and Development
|
Therapeutic Areas
|
Careers
|
Investor Area
|
Contact Us
|
中文
Announcements
2020-09-02 EASL 2020 (JKB-122 in Patients with Non-alcoholic Fatty Liver: A Phrase 2 Randomized Double-Blind Placebo-Control Study)
2020-06-19 TaiwanJ Pharmaceuticals signed up an MTA with Merck healthcare KGaA (FWB：MRK)
2019-03-08 TaiwanJ Pharmaceuticals Obtained US$26M Deal for Licensing and Co-Development Contract with Newsoara Biopharma on JKB-122 Asian Rights
2019-01-22 TaiwanJ Pharmaceuticals Announces Positive Results from Phase 2 Orphan Drug Designation Study of JKB-122 on Autoimmune Hepatitis (AIH)
more
Pipeline
JKB-122
TJC0133
TJC0265
TJC0316
TJC0434
TJC0545
...
Core Technology
TLR4
Autotaxin
NOX
HDAC
...
Company
|
NEWS
|
Research and Development
|
Therapeutic Areas
|
Careers
|
Investor Area
|
Contact Us
|
Address: Rm. D207, NO.2, Sec.2, ShengYi Rd., Zhubei City, Hsinchu County 30261, Taiwan (R.O.C) (Hsinchu Biomedical Science Park) Phone: 03-6587721 E-MAIL： info@taiwanj.com Fax：03-6587787
